Drug intelligence / Profile preview

DSXS-1411

Development stage: Preclinical
Lead developer: Taro
Modality: Small Molecules
Administration: Topical

Overview

DSXS-1411 is a small molecule drug candidate that has been investigated for the treatment of immune system diseases, particularly skin conditions such as psoriasis of the scalp. As of the latest available information, its highest reported development phase is "pending," with no completed clinical trials or approvals documented. The specific mechanism of action and molecular target for DSXS-1411 have not been disclosed in public sources. There are no known brand names or alternative names associated with this compound, and it does not appear to be approved or marketed in any country[4].

Beyond the preview

Go deeper on DSXS-1411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DSXS-1411.

Explore the full profile